Clinical

Learn more about how the St. Jude Good Manufacturing Practice facility is manufacturing lifesaving therapeutics for children with cancer and catastrophic diseases

Research in integrated, molecular diagnostics gave Fletcher Fazenbaker’s family something they thought they’d never get — a diagnosis and treatment plan.

Discover how St. Jude researchers are influencing sickle cell disease treatment globally.

At St. Jude, clinical trial SJiMB21 seeks to provide treatment strategies for infants and young children diagnosed with medulloblastoma that place the patient, not just the tumor, at the center of care.

Psychological, social and behavioral research sheds light on the needs of adolescents and young adults with cancer.

St. Jude received the hospital’s first expanded access designation from the FDA for use of PET scans with [11C]Methionine a tracer that makes imaging results clearer.

The St. Jude Methodist Sickle Cell Disease Transition Clinic helps patients move from pediatric to adult care, an important stage where patients often experience roadblocks to maintaining their health.

A St. Jude clinical trial launched more than 25 years ago has helped to transform understanding and care for children with the brain tumor craniopharyngioma.

Flexible and tailored implementation strategies helped pediatric cancer centers across Latin America scale up a proven quality improvement strategy.

What lessons can be learned from the remarkable success of SAFER Ukraine?